

Medical Drug Formulary Recommendations - ASE/PSE December 2024

Drug	Treating Diagnosis	EBD / EBRx / HA Recommendation	HA Coverage Policy (if applicable)	Comment	Cost	Commission Decision (12/5/2024)	Board of Finance Decision
Fluzone Quad	quadrivalent flu vaccine	No EBRx Restrictions	Cover per ACIP recommendations	2024 Quadrivalent formula	not available yet	Approve Recommendation	Approve Recommendation
Audenz	flu vaccine	No EBRx Restrictions	Cover per ACIP recommendations	National Stockpile	\$0	Approve Recommendation	Approve Recommendation
Ocrevus Zunovo	Multiple sclerosis	Cover with PA		Use the same criteria as Ocrevus IV, SC into abdomen over 10 min	\$94,630 per year	Approve Recommendation	Approve Recommendation
Vyalev	Parkinson's Disease	Exclude		Continuous infusion worn as a belt. Dose can be adjusted. Will rereview Parkinsons class and consider more flexible dosing in 1Q25.	\$32,976 per year	Approve Recommendation	Approve Recommendation
Pavblu	Wet AMD, Macular Edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy	No EBRx Restrictions	Covered by FDA label	Intraocular Injectable, Biosimilar of Eylea.	\$23,976 per year	Approve Recommendation	Approve Recommendation
Eylea	Wet AMD, Macular Edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, Retinopathy of Prematurity	Exclude		Prefer the biosimilar (Pavblu). EBRx will mail letters to impacted members (113)	\$26,640 per year	Approve Recommendation	Approve Recommendation
Vyloy	gastric or gastroesophageal junction adenocarcinoma	Cover with PA		Significant PFS and OS results are driven by gastric cancer due to sample size.	\$20,480 per 28 days	Approve Recommendation	Approve Recommendation
Infergen		Remove from Formulary		Discontinued		Approve Recommendation	Approve Recommendation
Tegsedi		Remove from Formulary		Discontinued		Approve Recommendation	Approve Recommendation
Octreotide gluteal IM inj	Acromegaly, Carcinoid, VIPomas	No EBRx Restrictions	Same as brand	generic Sandostatin LAR depot	\$63,151 - \$94,564 per year	Approve Recommendation	Approve Recommendation
Sandostatin LAR depot	Acromegaly, Carcinoid, VIPomas	Exclude		generic available, no longer cover the brand name, EBRx will mail letters to impacted members (11)	\$66,475 - \$99, 541 per year	Approve Recommendation	Approve Recommendation
Tevimbra	Esophageal squamous cell carcinoma	Cover with PA		Improved OS modestly with reduction in toxicity	\$16,652 per 28 days	Approve Recommendation	Approve Recommendation
Rybrevant	New indication: non-small cell lung cancer	Cover with PA		New indication (given in adjunct with Lazcluze) does not improve OS. Adding PA to make sure only initial diagnosis is covered	\$2,500 per 28 days	Approve Recommendation	Approve Recommendation